IL-17D reprograms CD93(+) antigen-presenting cells in the glioblastoma microenvironment.

IL-17D reprograms CD93(+) antigen-presenting cells in glioblastoma, extending survival by substantial reorganization of the tumor immune environment.

• Why it matters: Glioblastoma’s immunosuppressive microenvironment hampers immunotherapy effectiveness, and understanding how to reverse this suppression could improve treatment outcomes.
• What they did: Researchers restored IL-17D expression in orthotopic GBM models, revealing that IL-17D interacts with CD93 and SCARB1 to activate signaling pathways that convert tolerogenic cells into active antigen presenters.
• The result: Restoring IL-17D reshapes the immune landscape of GBM, offering a promising therapeutic avenue to boost immunotherapy efficacy by reprogramming tumor-associated immune cells.